Veronica Gambillara Fonck

Veronica joined the Pureos Bioventures team as a Partner in 2022. She has been a founder CEO of Glycoera, a Zurich-based company with a glycoengineering platform for novel antibodies in autoimmune diseases, oncology and neurology. She was also a co-founder and the CEO of LimmaTech Biologics, a spin-off of GlycoVaxyn to service GSK. Before that, Veronica was on the executive team of GlycoVaxyn developing innovative vaccines for infectious diseases. She was instrumental in the acquisition of the company by GSK in 2015. Veronica is a bioengineer with a Ph.D. in life science from the EPFL Lausanne.